-

Apyx Medical Corporation to Participate in the Piper Sandler 34th Annual Healthcare Conference

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Piper Sandler 34th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY. Management will participate in fireside chat on Wednesday, November 30 at 11:00 a.m. ET.

A live audio webcast of the fireside chat will be provided under the ‘Company Events’ section of the Apyx Medical Corporation investor relations website at https://apyxmedical.com/investor_relations/. A replay of the webcast will be available on the investor relations website following the conference.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Contacts

Investor Relations:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com

Apyx Medical Corporation

NASDAQ:APYX

Release Versions

Contacts

Investor Relations:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com

More News From Apyx Medical Corporation

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the journal, Plastic and Reconstructive Surgery—Global Open, featuring the results of study which compared the use of Renuvion’s Helium Plasma Technology to InMode’s Bipolar RF System (“Bipolar RF”) following li...

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced...

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question...
Back to Newsroom